Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
J. Sybil Biermann, Angela C. Hirbe, Shivani Ahlawat, Nicholas M. Bernthal, Odion Binitie, Sarah G Boles, Brian E. Brigman, Alexandra K. Callan, Cara A. Cipriano, Lee D. Cranmer, Jessica Davis, Eric D. Donnelly, Michael J. Ferguson, Ann Graham, John Groundland, Matthew Hess, Susan M. Hiniker, Margo Hoover‐Regan, Jason L. Hornick, Brandon Jonard, Joseph Kuechle, Dieter M. Lindskog, Joel Mayerson, Sean V. McGarry, Carol D. Morris, Daniel J. Olson, Peter S. Rose, Victor M. Santana, Robert L. Satcher, Herbert S. Schwartz, Rebecca M. Shulman, Steven W. Thorpe, Breelyn A. Wilky, Rosanna Wustrack, Janet Yoon, Lisa E. Hang, Frankie Jones, Nicholas Sansone, Megan Lyons
Abstract
Ewing sarcoma and osteosarcoma constitute 36% of all primary bone cancers. However, these 2 subtypes represent the most commonly diagnosed bone cancer types in the pediatric and adolescent population. Although still largely unknown, certain genetic mutations, rearrangements, and/or predisposition syndromes likely play a role in the pathogenesis of bone cancer. Osteosarcoma may also develop as a direct result of the long-term side effects of radiation therapy. With the implementation of a multimodality approach to treatment, including multiagent neoadjuvant and adjuvant chemotherapy regimens, targeted therapy options, surgery, and radiation, individuals with Ewing sarcoma and osteosarcoma are showing higher cure rates and improved overall survival. The NCCN Guidelines for Bone Cancer provide a consensus and evidence-based framework for the workup, management, and surveillance of local and recurrent/metastatic disease.